Implementing Newer Biologic Therapies to Improve Economic and Clinical Outcomes in Patients with Moderate to Severe Atopic Dermatitis

A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive from the live session from the 2018 Spring Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from August 1, 2018 to August 1, 2019

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.

 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This presentation is supported by an educational grant from
Sanofi Genzyme and Regeneron Pharmaceuticals

Description:
Atopic dermatitis (AD) is a common, chronic inflammatory skin disease characterized by periods of acute disease flare that may include painful burning sensations and persistent itching. AD occurs more frequently in adulthood, is often accompanied by co-morbidities such as rhinitis and asthma, and can severely affect quality of life. There are approximately 17.8 million people with moderate to severe eczema or atopic dermatitis in the United States with an estimated annual direct and indirect cost of approximately $5 billion dollars. This condition evolves from a combination of skin barrier defects and immune-mediated responses involving activated T-helper cells and related cytokines. Current atopic dermatitis treatments attempt to reduce inflammation and itchiness to maintain the protective integrity of the skin and have shown the ability to manage the disease in the short term but have had troubles with long term efficacy. Thankfully advances in the understanding of the pathophysiology underlying atopic dermatitis is resulting in the development of targeted therapies for children and adult patients with this disease. Fortunately, several new treatments, including novel monoclonal antibodies or targeted therapies, such as JAK and PDE4 inhibitors, have shown improved efficacy and safety, offering patients the potential for improved outcomes and quality of life.


Upon Completion of this activity, participants will be able to:

  • Analyze the impact of inadequately treated moderate-to-severe atopic dermatitis (AD) on physical and mental health, quality of life, costs and work productivity in adult patients

  • Discuss new treatments, signaling pathways and molecular actors that play a role in the pathogenesis of AD

  • Design individualized treatment plans for adults with moderate-to-severe AD based on current guideline recommendations, the safety and efficacy of new and emerging treatment options, comorbidities, and patient quality of life

  • Explore key points and strategies that managed care professionals and payors need to know about newer biologic therapies in moderate-to-severe AD

  • Examine communication and education strategies to improve adherence to AD treatment strategies and assess the effects of treatment on patient quality of life
     

Faculty: Zelma C. Chiesa Fuxench, MD, MSCE, FAAD
Assistant Professor of Dermatology
Department of Dermatology
University of Pennsylvania Perelman School of Medicine

Disclosure:

Dr. Chiesa Fuxench serves as a consultant to the Asthma and Allergy Foundation of American and the National Eczema Association. She served as the principle investigator for atopic dermatitis clinical trials for Sanofi/Regeneron, Vanda and Tioga Pharmaceuticals. She has served as a speaker for CME programs supported by educational grants from Sanofi/Regeneron. Her presentation has been peer reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no relevant financial relationships to disclose.
Jeremy Williams has no relevant financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category I creditsTM.

The American Association of Managed Care Nurses is accredited as a provider of continuing nursing
education by the American Nurses Credentialing Center’s Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing
nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This presentation is supported by an educational grant from
Sanofi Genzyme and Regeneron Pharmaceuticals

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue